Daily non-political popular news in brief.

Studies highlight 'real world' use, safety of drug-eluting stents

03-26-2007 · EurekAlert!

Research presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent -- a dangerous complication -- and adherence and responsiveness to anti-clotting medication.

Keywords: studies, highlight, real, world, safety, drug-eluting, stents, study, drug, eluting, stent

« Previous | Next »

Similar news on "Studies highlight 'real world' use, safety of drug-eluting stents":

Bioabsorbable stent shows excellent performance
03-24-2007 · EurekAlert!
The use of slow-release drugs in stents (drug-eluting stents) has dramatically reduced restenosis rates after percutaneous coronary intervention. However, these permanent metal devices may impair coronary imaging, predispose patients to late stent thrombosis, prevent positive remodeling and hinder revascularization. A study presented today at the American College of Cardiology's Innovation in Intervention: i2Summit assesses the safety and performance of a bioabsorbable stent that, if effective, could eliminate several of the problems associated with metallic stents.
Similar news · Read more »
Second-generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
Second generation drug-eluting stent system challenges current gold standard
03-24-2007 · EurekAlert!
While research shows that drug-eluting stents effectively reduce restenosis and revascularization compared to bare-metal stents, questions surrounding the safety of drug-eluting stents continue to dominate headlines. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit surveys the safety and efficacy of the second generation Xience Everolimus Eluting Coronary Stent System (EES), compared to the current gold standard paclitaxel-eluting stent (PES), to determine if it offers similar or enhanced outcomes.
Similar news · Read more »
Drug-eluting and bare-metal stents equal in risk of blood clots, heart attacks and death
03-24-2007 · EurekAlert!
Although the use of stents to treat coronary artery disease has soared during the past decade thanks to novel equipment and new implant techniques, clinical data has recently raised concerns around the safety of drug-eluting stents (DES) and their risk of post-procedure complications. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit compared rates of complications in thousands of patients who received bare-metal stents (BMS) or DES.
Similar news · Read more »
Studies led by Rhode Island Hospital confirm safety and efficacy
11-17-2006 · EurekAlert!
Following two studies of patients who were treated with cardiac stents, physicians at Rhode Island Hospital continue to recommend drug-eluting stents as a safe and effective treatment.
Similar news · Read more »
Tip sheet, Annals of Internal Medicine, Dec. 18, 2007, issue
12-17-2007 · EurekAlert!
The following articles are in the upcoming issue of Annals of Internal Medicine: "Task Force Does Not Recommend Screening for Carotid Artery Stenosis"; "Vitamin D is Standard Treatment for CKD Despite Evidence"; "Organ Donation Laws Need Revising so that Doctors Give Priority to Care for the Donor Rather than The Organ"; "Study Finds Insufficient Evidence to Decide the Most Effective Treatment to Prevent Osteoporotic Fractures"; and "Balancing Efficacy and Safety of Drug-Eluting Stents."
Similar news · Read more »
SCAI president testifies before FDA on safety of drug-eluting stents
12-07-2006 · EurekAlert!
In testimony before the Food and Drug Administration (FDA), Gregory J. Dehmer, MD, president of the Society for Cardiovascular Angiography and Interventions (SCAI), today urged a review panel to evaluate new data on the safety of drug-eluting stents (DES) from the perspective of prior developments in the history of coronary intervention, and with an appreciation for the balance of benefits and risks that guides all clinical decision-making.
Similar news · Read more »
Risk and outcome similar for bypass surgery, drug-eluting stents
04-19-2007 · EurekAlert!
Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.
Similar news · Read more »
Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
01-02-2007 · EurekAlert!
Use of the drug pexelizumab immediately before and for 24 hours after stent placement or angioplasty for certain heart attack patients did not have any significant treatment effect compared to placebo, according to a study in the Jan. 3 issue of JAMA. The medication had shown promise in preliminary studies.
Similar news · Read more »
Mayo Clinic study shows drug-eluting stent use in heart patients determined more by insurance type
03-27-2007 · EurekAlert!
If you want the best technology available to relieve blocked blood flow to the heart, the choice is a drug-eluting stent. And you are most likely to obtain the drug-eluting stent for reasons that have nothing to do with your medical condition, a new Mayo Clinic study shows.
Similar news · Read more »